Phase 2 Generalized Myasthenia Gravis Clinical Trials
9 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–9 of 9 trials
Recruiting
Phase 2Phase 3
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Myasthenia GravisGeneralized Myasthenia Gravis
Kyverna Therapeutics66 enrolled17 locationsNCT06193889
Recruiting
Phase 2
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Generalized Myasthenia Gravis
Amgen15 enrolled1 locationNCT06987539
Recruiting
Phase 2Phase 3
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
UCB Biopharma SRL8 enrolled9 locationsNCT06055959
Recruiting
Phase 2Phase 3
A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
UCB Biopharma SRL12 enrolled14 locationsNCT06149559
Recruiting
Phase 2Phase 3
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
Generalized Myasthenia Gravis
Shanghai Jiaolian Drug Research and Development Co., Ltd104 enrolled18 locationsNCT06447597
Recruiting
Phase 2Phase 3
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
argenx12 enrolled20 locationsNCT06392386
Recruiting
Phase 2
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Myasthenia GravisGeneralized Myasthenia Gravis (gMG)Generalized Myasthenia Gravis+3 more
argenx70 enrolled9 locationsNCT07284420
Recruiting
Phase 1Phase 2
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
Novartis Pharmaceuticals15 enrolled10 locationsNCT06704269
Recruiting
Phase 2Phase 3
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
argenx12 enrolled25 locationsNCT04833894